Imeglimin, a novel, first in-class, blood glucose-lowering agent: a systematic review and meta-analysis of clinical evidence

Authors

  • Thomas SJ Crabtree Sandwell and West Birmingham Hospitals NHS Trust University of Nottingham University of Derby and Burton NHS Trust
  • Ralph A DeFronzo University of Texas Health Science Center, San Antonio, Texas, USA
  • Robert E J Ryder City Hospital, Birmingham, UK
  • Clifford J Bailey Life and Health Sciences, Aston University, Birmingham, UK

DOI:

https://doi.org/10.15277/bjd.2020.247

Keywords:

type 2 diabetes, mitochondria, imeglimin, glimins, tetrahydrotriazine, systematic review, meta-analysis

Abstract

Imeglimin is a novel, first in-class, blood glucose-lowering agent which acts via a mitochondrial mechanism to enhance glucose-induced insulin secretion, decrease hepatic glucose output and increase glucose uptake by skeletal muscle. A systematic review and meta-analysis of randomised controlled clinical trials (RCTs) with imeglimin in adults with type 2 diabetes was undertaken. Of 45 articles identified, five were RCTs but, due to the format of the data, only three could be combined in a meta-analysis (total n=180 participants). A random-effects model found that imeglimin 1500 mg twice daily as monotherapy and add-on to metformin or sitagliptin was associated with reductions of HbA1c by −0.63% (95% CI −0.84 to −0.42) (−6.6 mmol/mol, 95% CI −8.8 to −4.4) and reductions of fasting plasma glucose by −0.52 mmol/L (95% CI −0.80 to −0.24) compared with placebo. Adverse events were minimal, mostly gastrointestinal, and without hypoglycaemia. It is concluded that imeglimin displays promising improvements in HbA1c and fasting plasma glucose and is generally well tolerated.

References

DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers 2015;1:15019. https://doi.org/10.1038/nrdp.2015.19

Vial G, Chauvin M-A, Bendridi N, et al. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes 2015;64:2254–64. https://doi.org/10.2337/db14-1220

Patti M-E, Corvera S. The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev 2010;31:364–95. https://doi.org/10.1210/er.2009-0027

Petersen KF, Dufour S, Befroy D, et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004;350:664−71. https://doi.org/10.1056/NEJMoa031314

Li J, Shirakawa, Y, Togashi T, et al. Effects of imeglimin on insulin secretion, beta-cell proliferation, or apoptosis in mouse islets. J Diabetes Invest 2018;9:12. https://doi.org/10.1111/jdi.12937

Pacini G. Mari A, Fouqueray P, et al. Imeglimin increases glucose-dependent insulin secretion and improves beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2015;17:541−5. https://doi.org/10.1111/dom.12452

Hallakou-Bozec S, Kergoat M, Bolze S, Lebovitz HE. Imeglimin preserves beta cell function and mass in male zucker diabetic fatty rats. Endocr Pract 2017; 23:1. https://d1io3yog0oux5.cloudfront.net/_938fdfc18803a883031931f148c6cae6/poxelpharma/db/419/2331/file/2016-11-17_WCIRDC+Imeglimin+beta+cell+function+and+mass+Final.pdf

Lablanche S, Tubbs E, Cottet-Rousselle C, et al. Imeglimin protects INS-1 cells and human islets against high glucose- and high fructose-induced cell death by inhibiting the mitochondrial PTP opening. Diabetes 2018;67(Suppl 1):81-OR. https://doi.org/10.2337/db18-81-OR

Detaille D, Vial G, Borelet A-L, et al. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discovery 2016;2:15072. https://doi.org/10.1038/cddiscovery.2015.72

Lachaux M, Nicol L, Hamzaou M, et al. Imeglimin protects from diabetic cardiomyopathy in the obese zucker rat. Diabetes 2017;66(Suppl 1):2054-P.

Lachaux M, Souille M, Remy-Jouet I, et al. Acute imeglimin treatment improves metabolic syndrome-related cardiac and coronary endothelial dysfunction in the zucker fa/fa rat. Eur Heart J 2018;39:484−5.

Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab 2012;14:852−8. https://doi.org/10.1111/j.1463-1326.2012.01611.x

Fouqueray P, Pirags V, Inzucchi SE, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 2013;36:565−68. https://doi.org/10.2337/dc12-0453

Fouqueray P, Pirags V, Diamant M, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. Diabetes Care 2014;37:1924−30. https://doi.org/10.2337/dc13-2349

Dubourg J, Ueki K, Watada H, et al. Imeglimin monotherapy in Japanese patients with type 2 diabetes: results from a randomised, 24-week, double-blind, placebo-controlled, phase IIb trial. Diabetologia 2017;60(Suppl 1):843.

Poxel Pharma. Poxel and Sumitomo Dainippon Pharma announce positive top-line results for imeglimin phase 3 trial (TIMES 1) in Japan for the treatment of type 2 diabetes. 9 April 2019. https://www.poxelpharma.com/en_us/news-media/press-releases/detail/117/poxel-and-sumitomo-dainippon-pharma-announce-positive (accessed 23 March 2020).

Bailey CJ. The current drug treatment landscape for diabetes and perspectives for the future. Clin Pharmacol Ther 2015;98:170−84. https://doi.org/10.1002/cpt.144

Published

2020-06-05

Issue

Section

Original Research

Most read articles by the same author(s)

1 2 > >>